Back to top
more

Cardinal Health (CAH)

(Real Time Quote from BATS)

$113.12 USD

113.12
546,597

-0.05 (-0.04%)

Updated Sep 16, 2024 03:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (160 out of 251)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Here's Why You Should Retain Masimo (MASI) Stock for Now

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

Here's Why You Should Retain Neogen (NEOG) Stock for Now

Investors are optimistic about Neogen's (NEOG) strong performance across its Animal Safety and Food Safety segments.

Here's Why You Should Retain Abbott (ABT) Stock for Now

Investors are optimistic about Abbott (ABT) owing to continued growth in the Diabetes business.

Edwards Lifesciences (EW) Gains on Innovation, Margin Growth

In Edwards Lifesciences' (EW) Smart Recovery portfolio, the adoption of FloTrac and ClearSight sensors remains strong.

Integer Holdings (ITGR) Q4 Earnings Beat Estimates, Margins Up

Integer Holdings' (ITGR) fourth-quarter results reflect robust Medical and Non-Medical Sales, besides strength in all the product lines.

Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar?

Style Box ETF report for SPYD

Benjamin Rains headshot

3 Great Value Stocks to Buy Now for Steady Long-Term Growth

Exploring three highly-ranked value stocks with resilient businesses--(CAH), (GPK) and (BJ)--that investors might want to consider buying amid lingering inflation and for stable long-term expansion.

PacBio (PACB) Q4 Earnings Match Estimates, Revenues Top

Despite robust Consumables revenues, PacBio (PACB) witnesses overall soft performance in the fourth quarter.

Nevro (NVRO) Q4 Earnings Lag Estimates, Revenues Beat

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q4, partly owing to robust domestic performance.

Zacks.com featured highlights include Microchip Technology, Caterpillar, Xcel Energy, Cardinal Health and Archer-Daniels-Midland

Microchip Technology, Caterpillar, Xcel Energy, Cardinal Health and Archer-Daniels-Midland are part of the Zacks screen of the Week article.

Syneos Health (SYNH) Q4 Earnings Beat Estimates, Margins Down

Higher reimbursable expenses and growth in Deployment Solutions contribute to Commercial Solutions revenue growth at Syneos Health (SYNH).

Bio-Rad (BIO) Q4 Earnings Miss Estimates, Operating Margin Up

Excluding COVID-related sales, Life Science revenues at Bio-Rad (BIO) increase 28.1%, primarily driven by Droplet Digital PCR, process chromatography, Western blotting and qPCR products.

Cardinal Health, Inc. (CAH) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Cardinal (CAH). This makes it worthwhile to examine what the stock has in store.

AMN Healthcare (AMN) Q4 Earnings, Revenues Beat Estimates

Despite AMN Healthcare's (AMN) robust results in the majority of its segments, it records a soft overall Q4 performance.

Amedisys (AMED) Q4 Earnings Beat, Operating Margin Dips

Amedisys (AMED) delivers strong Home Health performance in the fourth quarter amid cost pressure.

Shockwave Medical's (SWAV) Q4 Earnings Top, Revenues Surge Y/Y

Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.

Here's Why You Should Retain Inari Medical (NARI) Stock Now

Inari Medical (NARI) continues benefiting from its commitment to understand the venous system. However, dependency on the wide adoption of products is a concern.

Here's Why You Should Retain OPKO Health (OPK) Stock for Now

Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.

QuidelOrtho (QDEL) Q4 Earnings Top Estimates, Margins Down

QuidelOrtho (QDEL) reports robust overall top-line results in fourth-quarter 2022, despite disappointing segmental and geographical performances on a reported basis.

LabCorp (LH) Q4 Earnings Surpass Estimates, Margins Fall

The severe foreign exchange headwind, inflationary pressure and the ongoing Ukraine/Russia crisis impact LabCorp's (LH) business performance in Q4.

Boston Scientific (BSX) Gains From New Buyouts, Cost Woes Stay

Boston Scientific's (BSX) EMEA business grows above market, supported by the company's ongoing investments in emerging markets.

West Pharmaceutical (WST) Q4 Earnings Beat, Order Book Strong

West Pharmaceutical's (WST) fourth-quarter results reflect sustained growth in non-COVID-19 demand amid dismal overall performance.

Here's Why You Should Add Cooper Companies (COO) Stock Now

Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.

Sweta Killa headshot

5 Dividend Growth Stocks to Buy Amid Market Volatility

Microchip Technology (MCHP), Caterpillar (CAT), Xcel Energy (XEL), Cardinal Health (CAH) and Archer-Daniels-Midland (ADM) could be compelling dividend growth picks amid market volatility.

Quest Diagnostics (DGX) New Pact to Boost Laboratory Services

Quest Diagnostics' (DGX) recent agreement is intended to offer advanced and quality clinical laboratory services in the greater New York region and beyond.